Skip to main content

Blog

Food Allergies – Not Only a Childhood Disease

Researchers estimate the number of people with food allergies in the U.S. to be 32 million. It breaks down to 6 million children and 26 million adults – more than previously thought. 1 It is common for food allergies to develop in childhood, but you can develop a food allergy at any age. Adults are more likely to develop allergies to crustacean shellfish (like crabs, lobster or shrimp), peanuts, milk, tree nuts and fin fish. 1 Adult-onset food allergies are generally life-long and are not...

FDA Approves ProAir HFA Generic, a Quick-Relief Medicine for Asthma

The U.S. Food and Drug Administration today approved the first generic of ProAir HFA (albuterol sulfate) Inhalation Aerosol for the treatment or prevention of bronchospasm in patients four years of age and older with reversible obstructive airway disease and the prevention of exercise-induced bronchospasm in patients four years of age and older.

CERTIFIED Baby Mattress Creates a Healthier Environment for Infants With Asthma and Allergies

Pure Zees recently announced the expansion of its innovative asthma & allergy friendly® mattresses into the U.S. market, unveiling a new U.S. website to help roll out multiple related products through 2020. The Irish-based company has secured coveted certification for their signature infant mattress from both Allergy Standards Limited of Ireland (ASL) and The Asthma and Allergy Foundation of America (AAFA).

February Advocacy Update: Over-the-Counter Medicines, Restaurant Safety and Cleaner Cars

Welcome to your February advocacy update. I’m Jenna Riemenschneider, director of advocacy at the Asthma and Allergy Foundation of America (AAFA). I am pictured above with AAFA board member Renuka Babu Brown and Senator Ed Markey's (D-MA) policy advisor Adam Axler. Over-the-Counter Drug Access and Cleaner Cars Rollbacks AAFA and other members of the Healthy Choices Coalition met with Representative Judy Chu's office. We asked her to co-sponsor the Restoring Access to Medication Act of 2019...

FDA Considers Biologic Dupilumab for Children Ages 6 to 11 Years With Moderate-to-Severe Atopic Dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Dr. Philip Norman: An AAFA Tribute to an Allergy Legend

If you’ve ever benefited from immunotherapy (allergy shots, SLIT or oral immunotherapy), you can thank Dr. Philip Sidney Norman. Dr. Norman put allergy research on the map. He is known as the “father of modern immunotherapy for allergic disease” and even coined the term “allergen immunotherapy.” As an allergist and researcher for more than 50 years, he published 237 research papers and more than 100 book chapters and reviews. And for many decades, he was an important part of AAFA.

We Fight, Support and Advocate in Honor of Those Who Have Lost Their Lives

Dear Friends, One of the hardest things we do at the Asthma and Allergy Foundation of America is have conversations with families who have lost loved ones to asthma. Our hearts break for them. We grieve along with them. After hearing these stories, we are determined to do even more for people with asthma and allergies. We understand that an asthma or allergy diagnosis can be a life-changing event. For those affected, we stand together, prepared not only to listen and to empathize, but also...

LUSTER Clinical Trial Results for People With Uncontrolled Moderate-to-Severe Asthma Announced

Novartis today announced topline results from its pivotal global Phase III LUSTER-11 and LUSTER-22 studies exploring the efficacy and safety of the investigational oral, once-daily, DP2 receptor antagonist fevipiprant (QAW039). The pooled analyses of the LUSTER trials did not meet3 the clinically relevant threshold for reduction in rate of moderate-to-severe exacerbation compared to placebo over a 52-week treatment period for either of the doses (150mg / 450 mg).

Post
×
×
×
×